AEON Biopharma, Inc. (AEON)
NYSEAMERICAN: AEON · Real-Time Price · USD
0.850
0.00 (0.00%)
Nov 7, 2024, 1:02 PM EST - Market open
AEON Biopharma Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 |
| Operating Revenue | - | - | - | - | 2.52 | 3.34 | Upgrade
|
| Other Revenue | - | - | - | - | - | 0.02 | Upgrade
|
| Revenue | - | - | - | - | 2.52 | 3.36 | Upgrade
|
| Revenue Growth (YoY) | - | - | - | - | -24.99% | 38.89% | Upgrade
|
| Cost of Revenue | - | - | - | - | - | 0 | Upgrade
|
| Gross Profit | - | - | - | - | 2.52 | 3.36 | Upgrade
|
| Selling, General & Admin | 18.97 | 19.79 | 13.68 | 11.15 | 11.59 | 46.04 | Upgrade
|
| Research & Development | 24.99 | 33.05 | 34.75 | 25.73 | 7.32 | 4.81 | Upgrade
|
| Operating Expenses | 43.96 | 52.84 | 48.43 | 36.88 | 18.91 | 51.73 | Upgrade
|
| Operating Income | -43.96 | -52.84 | -48.43 | -36.88 | -16.39 | -48.37 | Upgrade
|
| Interest Expense | - | - | - | - | -0.02 | -7.47 | Upgrade
|
| Interest & Investment Income | - | - | - | - | - | 0.72 | Upgrade
|
| Earnings From Equity Investments | - | - | - | - | - | 0.14 | Upgrade
|
| Other Non Operating Income (Expenses) | -52.23 | -17.19 | 0.29 | -0.14 | -0.12 | 0.01 | Upgrade
|
| EBT Excluding Unusual Items | -96.19 | -70.02 | -48.14 | -37.02 | -16.52 | -54.98 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | - | - | 0.35 | -42.7 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | - | - | - | 254.11 | Upgrade
|
| Legal Settlements | - | - | - | -28.97 | - | - | Upgrade
|
| Other Unusual Items | 138.67 | 33.39 | -4.42 | 10.35 | -16.74 | -10.76 | Upgrade
|
| Pretax Income | -305.52 | -384.63 | -52.56 | -55.64 | -32.91 | 145.67 | Upgrade
|
| Income Tax Expense | - | - | - | - | - | -14.65 | Upgrade
|
| Earnings From Continuing Operations | -305.52 | -384.63 | -52.56 | -55.64 | -32.91 | 160.32 | Upgrade
|
| Minority Interest in Earnings | - | - | - | - | - | 12.61 | Upgrade
|
| Net Income | -305.52 | -384.63 | -52.56 | -55.64 | -32.91 | 172.92 | Upgrade
|
| Preferred Dividends & Other Adjustments | - | - | - | - | 17.26 | 35.84 | Upgrade
|
| Net Income to Common | -305.52 | -384.63 | -52.56 | -55.64 | -50.17 | 137.08 | Upgrade
|
| Shares Outstanding (Basic) | 43 | 93 | 139 | 126 | 7 | 7 | Upgrade
|
| Shares Outstanding (Diluted) | 43 | 93 | 139 | 126 | 7 | 7 | Upgrade
|
| Shares Change (YoY) | -68.99% | -32.71% | 9.98% | 1813.86% | -0.74% | 0.58% | Upgrade
|
| EPS (Basic) | -7.10 | -4.12 | -0.38 | -0.44 | -7.61 | 20.78 | Upgrade
|
| EPS (Diluted) | -7.10 | -4.12 | -0.38 | -0.44 | -7.61 | 20.57 | Upgrade
|
| Free Cash Flow | -43.4 | -47.83 | -35.89 | -28.6 | -9.46 | -44.73 | Upgrade
|
| Free Cash Flow Per Share | -1.01 | -0.51 | -0.26 | -0.23 | -1.43 | -6.73 | Upgrade
|
| Gross Margin | - | - | - | - | 100.00% | 99.97% | Upgrade
|
| Operating Margin | - | - | - | - | -650.83% | -1440.87% | Upgrade
|
| Profit Margin | - | - | - | - | -1992.53% | 4083.44% | Upgrade
|
| Free Cash Flow Margin | - | - | - | - | -375.73% | -1332.29% | Upgrade
|
| EBITDA | -43.86 | -52.74 | -48.36 | -36.88 | -15.51 | -47.5 | Upgrade
|
| D&A For EBITDA | 0.1 | 0.1 | 0.07 | 0 | 0.88 | 0.88 | Upgrade
|
| EBIT | -43.96 | -52.84 | -48.43 | -36.88 | -16.39 | -48.37 | Upgrade
|
| Revenue as Reported | - | - | - | - | - | 3.36 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.